Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, announced that its phase III study of REVLIMID in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival. In the study, a doublet regimen of continuous oral lenalidomide in combination with low-dose dexamethasone demonstrated a statistically significant improvement in PFS compared to patients receiving a comparator arm with a triplet regimen consisting of melphalan, prednisone and thalidomide. The primary endpoint for the study was PFS. Secondary endpoints include overall survival, response rate, quality of life and safety. T he evaluation of safety and efficacy in the treatment arms is ongoing and the results of the study are planned to be presented at an upcoming medical meeting. Based on the results of the FIRST study, the company will commence discussions with regulatory authorities and plans to submit dossiers for registration in the US, Europe and other markets.